We report the case of a 58-year-old male presenting with giant cell myocarditis and myositis associated with thymoma following treatment with carboplatin and paclitaxel. The patient was diagnosed as having stage IVa thymoma. Acetylcholine receptor binding antibody titers were positive at 42 nmol/l, although the patient exhibited no symptoms of myasthenia gravis (MG). The patient was treated with a combination of carboplatin and paclitaxel. However, 18 days following administration of this second cycle of chemotherapy, the patient developed a low-grade fever. Twenty-one days after receiving the second cycle of chemotherapy, the patient was admitted to the Nagoya City University Medical School complaining of general fatigue. Serum levels of creatinine phosphokinase (7,271 U/l), alanine aminotransferase (469 U/l) and aspartate aminotransferase (561 U/l) were elevated. Electromyography revealed no evidence of a neuromuscular junction defect or myopathic process. The patient developed progressive muscle weakness and succumbed to the disease in hospital on day 9. An autopsy revealed thymoma invasion of the left parietal and visceral pleura, pericardium and diaphragm. Numerous skeletal muscle groups and myocardium exhibited diffuse lymphocytic infiltration. Although it has been suggested that myocardial disorders may occur in patients with thymoma and/or MG, the mechanism involved remains unknown. This second report may provide new data regarding giant cell myocarditis and myositis associated with thymoma following treatment with carboplatin and paclitaxel.
Introduction
Polymyositis and myocarditis associated with thymoma are exceptionally rare and are usually accompanied by myasthenia gravis (MG). In 1944, Giordano and Haymondo reported the first autopsied case with the four diseases, MG, thymoma, giant cell polymyositis and cardiomyositis (1) . In 1969, Burke and colleagues who had observed ST segment depression and T-wave inversion on the electrocardiogram (ECG) in one case, reported that the patient suddenly died due to rapid progression of heart failure (2) . In their study, Namba and colleagues reported 13 cases of giant cell polymyositis, cardiomyositis and thymoma (3). Gidron and colleagues reported a thymoma case with fatal myocarditis following treatment with carboplatin and paclitaxel (4). We experienced a similar case.
Case report
A 58-year-old male presented to Nagoya City University Medical School, Japan, with stage IVa type B2 thymoma. An asymptomatic, anterior mediastinal mass had been identified 2 years previously upon routine chest X-ray examination, but the patient had not received any treatment prior to presentation. A biopsy was performed at a local hospital and the tumor was diagnosed as a type B2 thymoma. Chest radiography revealed left pleural effusion and a widened mediastinum with multiple chest wall masses. Computed tomography (CT) revealed that the tumor existed in the anterior mediastinum and that multiple dissemination existed in the left thoracic cavity, with pleural effusion (Fig. 1) . Acetylcholine receptor binding antibody titers were positive at 42 nmol/l (normal <0.3 nmol/l), although the patient had no symptoms of MG. The study was approved by the Institutional Review Board of the hospital. The patient provided informed consent and received two courses of carboplatin, 550 mg and paclitaxel, 330 mg. No problems were experienced following the first cycle of chemotherapy.
However, 18 days after receiving the second cycle of chemotherapy, the patient developed a low-grade fever. Then, 21 days after receiving chemotherapy, the patient was admitted to hospital due to general fatigue. Physical examination was notable for mild diffuse muscle tenderness. Laboratory examination revealed that serum levels of creatinine phosphokinase (7271 U/l; normal, 62-287 U/l), alanine aminotransferase (469 U/l; normal 6-37 U/l) and aspartate aminotransferase (561U/l; normal 10-33 U/l) were elevated. Serum electro-lytes and calcium were normal. Viral titers were negative. An evoked electromyogram showed that electrical activity produced by the skeletal muscles was within the normal range. The patient tested negative for Tensilon (edrophonium chloride). CT revealed that the tumor size had increased. The patient developed progressive muscle weakness and suddenly succumbed in hospital on day 9.
An autopsy revealed that type B2 thymoma (Fig. 2) , invasion of the left pleura, pericardium, diaphragm and multiple dissemination existed in the left thoracic cavity, with pleural effusion. At autopsy the heart weighed 330 g and there was no evidence of valvular or significant coronary artery disease. Numerous skeletal muscle groups and the myocardium exhibited diffuse lymphocytic infiltration, predominantly by CD8-positive T cells. The inflammatory cells were predominantly mononuclear cells, including lymphocytes, plasma cells and macrophages. Multinucleated giant cells also existed in muscles and myocardium (Fig. 3) . In the existing literature, certain instances of the syndrome of giant cell myocarditis and polymyositis associated with invasive thymoma have been reported, and this case is also thought to belong to this syndrome.
Discussion
Thymoma is one of the most common tumors in the anterior mediastinum. Thymoma typically grows slowly when it is at the early stages. Conversely, a number of studies have shown poorer prognosis for patients with invasive thymomas (5,6). Since complete resection is often impossible for advanced-stage thymoma, multimodal treatment strategies are required (7) .
Polymyosis and myocarditis associated with thymoma are exceptionally rare and usually accompanied by MG (8, 9) . In a review of 377,841 autopsies over a 20-year period, Wakafuji and Okada (10) found myocarditis in 0.11% and giant cell myocarditis in 0.007% of cases. Giant cell myocarditis generally affects young to middle-aged adults of either gender (11) . It is characterized by acute heart failure, ventricular arrhythmias or heart block, which progress rapidly to mortality, usually within 10 days (12); although some cases showed a good response to steroid, azathioprine and cyclosporine therapy (9, 13, 14) . However, the mechanisms remain unknown, and it has been speculated in previous reports that antimyocardial or antiskeletal muscle antibodies may be responsible for the abnormalities.
Giant cell myocarditis usually occurs in isolation, but has been reported in association with a variety of autoimmune diseases (12, 15, 16) and chronic infections (17, 18) . It is diagnosed in approximately 1% of patients with thymoma (12) . Almost 30 cases have been reported worldwide thus far, and the present patient was the fourth case of thymoma associated with myositis and myocarditis in Japan (8, 19, 20) . However, all four were fatal cases. Tanahashi and colleagues reported that glucocorticoid pulse therapies were not effective (8) . Anecdotal reports and animal studies have suggested that immunosuppressive treatment may be effective (14, 21, 22) , but there are no randomized controlled trials to support this theory. There is some evidence to suggest an autoimmune process, and activated T lymphocytes appear to be important for myocarditis development. Myocarditis has been reported to recur in transplanted hearts (22, 23) . The defective immunity found in patients with thymoma is thought to result in a giant cell immune reaction against myofibers (16) . While on chemotherapy for invasive thymoma, our patient developed fatal fulminant polymyositis and myocarditis without clinical evidence of MG. An autoimmune mechanism was indicated by the diffuse infiltration of muscles by lymphocytes. Whether chemotherapy triggered this syndrome remains to be determined. Notably, 18 days after receiving the second cycle of chemotherapy, the patient developed high-grade fever. The infection may be correlated with neutropenia caused by chemotherapy, which may trigger the syndrome. Increased awareness of giant cell myocarditis in association with thymoma should lead to early recognition and treatment. This case was the second associated with fatal myocarditis and polymyositis following treatment with carboplatin and paclitaxel (4) .
